報價延遲最少15分鐘:2025/07/20 20:08 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.36 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.13/-1.66
|
|
企業價值
4.44M
|
| 資產負債 |
|
每股賬面淨值
1.11
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.31
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 20:08 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19). |
